Evidence map›Paper›PMID 42298682›Full record

ReviewJournal of ovarian research2026

Ceramide: a pivotal lipid mediator shaping female reproductive homeostasis and pathophysiology.

Wujia Wang, FangYi Zhang, Lixuan Huang, Jie Qiao, Xinyu Qi

Abstract readReview
In one paragraph

Review in Journal of ovarian research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Wujia Wang *Center for Reproductive Medicine, Department of Obstetrics and Gynecology, State Key Laboratory of Female Fertility Promotion, Peking University Third Hospital, Beijing, 100191, China.ORCID http://orcid.org/0009-0000-3616-4048
FangYi Zhang *Center for Reproductive Medicine, Department of Obstetrics and Gynecology, State Key Laboratory of Female Fertility Promotion, Peking University Third Hospital, Beijing, 100191, China.ORCID http://orcid.org/0009-0009-0778-2301
Lixuan HuangCenter for Reproductive Medicine, Department of Obstetrics and Gynecology, State Key Laboratory of Female Fertility Promotion, Peking University Third Hospital, Beijing, 100191, China.ORCID http://orcid.org/0009-0001-4241-3968
Jie QiaoCenter for Reproductive Medicine, Department of Obstetrics and Gynecology, State Key Laboratory of Female Fertility Promotion, Peking University Third Hospital, Beijing, 100191, China.ORCID http://orcid.org/0000-0003-2126-1376
Xinyu QiCenter for Reproductive Medicine, Department of Obstetrics and Gynecology, State Key Laboratory of Female Fertility Promotion, Peking University Third Hospital, Beijing, 100191, China. qixinyu@bjmu.edu.cn.ORCID http://orcid.org/0009-0000-4941-3947

Funding

Beijing Natural Science Foundation 7242162Beijing Research Ward Excellence Program BRWEP2024W0940901004Key Clinical Projects of Peking University Third Hospital BYSY2022045National Key Research and Development Program of China 2024YFC2707300Natural Science Foundation of China 82288102, 32541060,82571886
6 · The paper itself

Abstract

Ceramide, a central hub in sphingolipid metabolism, serves as a critical bioactive signalling mediator that integrates lipid metabolism with multiple signalling pathways, primarily promoting autophagy and apoptosis. It influences female reproductive homeostasis and pathophysiology through multiple dimensions: altered ceramide levels have been observed in various reproductive disorders-such as polycystic ovary syndrome (PCOS), premature ovarian insufficiency (POI) and endometriosis (EM)-as well as across the female lifespan. These changes impact key processes including gonadotropin release, follicular development, and uterine microenvironment homeostasis. This review systematically summarizes the effects of ceramide on female fertility, highlighting its role as a pivotal entry point for understanding reproductive endocrine disorders in women. Modulating ceramide levels may represent a promising therapeutic strategy to enhance fertility and promote female reproductive health.

Indexed as

CeramidesReproductionAnimalsFemaleHomeostasisHumansLipid MetabolismPolycystic Ovary SyndromeSignal TransductionCeramidesCeramidesFemale fertilityFemale reproductive health across the lifespanFollicular developmentOvarian diseasesReproductive healthUterine diseases

Identifiers

PMID42298682
PMCPMC13531753

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.